VR8
0.059
55.3%
KYN
0.03
-21.1%
BEO
0.12
50%
G11
0.2
-20%
IMM
0.056
27.3%
MQR
0.004
-20%
CMO
0.005
25%
ALB
0.049
-18.3%
EXT
0.005
25%
AM5
0.005
-16.7%
FZR
0.4
23.1%
CTQ
0.015
-16.7%
CRB
0.012
20%
MGU
0.005
-16.7%
LIO
0.012
20%
W2V
0.042
-16%
PKO
0.012
20%
PAR
0.24
-15.8%
1MC
0.033
17.9%
RVT
0.11
-15.4%
TZL
0.033
17.9%
SVG
0.006
-14.3%
EM2
0.007
16.7%
LEX
0.125
-13.8%
FEL
0.007
16.7%
RML
0.052
-13.3%
CTD
2.46
15.5%
CAZ
0.02
-13%
A8G
0.2
14.3%
FCT
0.007
-12.5%
CXU
0.12
14.3%
GT1
0.014
-12.5%
M96
0.008
14.3%
LIT
0.007
-12.5%
PCL
0.008
14.3%
OEL
0.007
-12.5%
YUG
0.049
14%
PLC
0.007
-12.5%
BPM
0.25
13.6%
ZEU
0.007
-12.5%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

EBR Systems (ASX:EBR): How the WiSE® Coupler was developed to support implantation

Transcription of The Stock Network Interview with EBR Systems (ASX:EBR), Senior Director of Research & Development Mark Hirotsuka Lel Smits: EBR Systems is advancing cardiac resynchronization therapy with the world’s only leadless pacing technology designed for heart failure patients. The company’s WISE CRT system delivers wireless pacing directly inside the heart, offering an alternative to […]

GoldArc Resources (ASX:GA8): Building a bigger Leonora gold hub as drilling accelerates

Transcription of The Stock Network Interview with GoldArc Resources (ASX:GA8), Managing Director Paul Stephen Lel Smits: Gold Arc Resources is rapidly consolidating its position across Western Australia’s prolific Leonora and Kukaini districts, with drilling extending gold anomalies and high-grade results continuing to emerge across its portfolio. Ahead of presenting at Sydney Mining Club, I’m joined […]

Argo Investments (ASX:ARG): Finding income and the human edge in the age of AI

Transcription of The Stock Network Interview with Argo Investments (ASX:ARG), Managing Director Jason Beddow Lel Smits: As artificial intelligence reshapes investment markets, the value of human judgment experience and active management remains critical. Argo Investments, one of Australia’s oldest listed investment companies, is navigating this challenging environment while maintaining its focus on delivering sustainable income […]

Myopharm: Advancing TriGlytza® as a new treatment for Type 2 diabetes

Transcription of The Stock Network Interview with Myopharm, CEO and Executive Chair Karinza Phoenix Lel Smits: Myopharm is developing treatments for metabolic and inflammatory diseases led by its type 2 diabetes drug candidate TriGlytza. A recent preclinical study achieved its key HbA1c endpoint and reported stronger results than metformin over one month of treatment. I’m […]

Change Financial (ASX:CCA): Record results mark maiden full year profit

Transcription of The Stock Network Interview with Change Financial (ASX:CCA), CEO Tony Sheehan Lel Smits: Change Financial has delivered a landmark FY26 result, achieving its maiden four-year profit and beating upgraded revenue and EBITDA guidance. Revenue grew 21% while underlying EBITDA surged 17 times and the company’s Vertex and Pass platform continues to scale rapidly […]

Imagion Biosystems (ASX:IBX): How MagSense® is moving towards Phase 2 clinical trials

Transcription of The Stock Network Interview with Imagion Biosystems (ASX:IBX), Chair Bob Proulx Lel Smits: Imagium Biosystems is advancing a new approach to cancer detection with MagSense, its non-radioactive bio-safe molecular MRI imaging agent designed to help clinicians detect cancer earlier and with greater precision.Imagion Imagium Biosystems is initially focused on HER2 plus breast cancer […]